ESR1 and neoplasm: Compared with UBE2M silencing or fulvestrant treatment alone, the combination of UBE2M silencing and fulvestrant inhibited tumor growth more significantly, suggesting that UBE2M silencing improved the sensitivity of ER+ breast cancer cells to fulvestrant (Fig. 6B–D).